Back To Normal? US FDA Schedules In-Person Meeting But Pauses Non-COVID Guidance Development

 
• By Derrick Gingery
  
Compass and keyboard
FDA's recent actions seem to be aiming at different points on the compass as it assesses how the pandemic is affecting operations.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership